KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Payables (2016 - 2025)

Historic Payables for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $255.8 million.

  • West Pharmaceutical Services' Payables rose 1404.37% to $255.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.8 million, marking a year-over-year increase of 1404.37%. This contributed to the annual value of $239.3 million for FY2024, which is 127.89% down from last year.
  • West Pharmaceutical Services' Payables amounted to $255.8 million in Q3 2025, which was up 1404.37% from $239.0 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Payables peaked at $255.8 million during Q3 2025, and registered a low of $188.9 million during Q3 2022.
  • In the last 5 years, West Pharmaceutical Services' Payables had a median value of $224.3 million in 2024 and averaged $225.0 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 2938.57% in 2021, then tumbled by 905.15% in 2022.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Payables stood at $232.2 million in 2021, then fell by 7.24% to $215.4 million in 2022, then grew by 12.53% to $242.4 million in 2023, then decreased by 1.28% to $239.3 million in 2024, then increased by 6.9% to $255.8 million in 2025.
  • Its last three reported values are $255.8 million in Q3 2025, $239.0 million for Q2 2025, and $228.4 million during Q1 2025.